Amdocs upgraded to Outperform from Perform at Oppenheimer Oppenheimer upgraded Amdocs with a $47 price target citing the company's solid Q1 results and slightly improved FY14 guidance. Opco says the stock tends to outperform in uncertain market conditions.
Amdocs reported interest in Comverse billing unit makes sense, says JPMorgan After Israel's Globes said that Amdocs (DOX) is in advanced talks to buy Comverse's (CNSI) billing unit for $300M-$400M, JPMorgan said it believes Comverse has had the unit up for sale for quite some time and that such a deal could make strategic and financial sense for Amdocs. However, the firm added that such a deal might suggest that Amdocs management sees limited opportunities for organic growth in the near-term. JPMorgan has a Neutral rating on Amdocs shares.
Amdocs in discussions to acquire Comverse billing division, Globes says Amdocs (DOX) is in discussions to acquire Comverse's (CNSI) billing division for $300M-$400M, according to Globes. Reference Link